Navigating radiopharmaceutical dynamics in Ra-223 alpha emitter radiotherapy: Implications for treatment optimization and personalization

It has recently come to light that radiotherapy with Ra-223 (alpha emitter) radionuclides can be an effective therapeutic option for a variety of different cancers. A comprehensive knowledge of biodistribution, accumulation, and clearance pathways, as well as radiopharmaceutical kinetics, is required for an accurate assessment of therapy efficacy and a reduction in the severity of any adverse effects that the treatment may cause. Using the absorbed dose, measured in mGy/MBq, researchers can explore each organ in adult male and female animals and the differential accumulation, removal rates, and clearance pathways of radiopharmaceuticals. Because of their high linear energy transfer (LET) and limited range in tissue, the use of alpha emitter radionuclides in radiotherapy has attracted substantial interest recently. These properties allow for targeted therapy with minimum damage to the healthy cells in the surrounding area. This article provides a complete literature analysis on applying alpha emitter radionuclides in radiotherapy. The review focuses on zutilizing two well-known software tools, WinAct 1.0 and IDAC-Dose 2.1, for dosimetry calculations and treatment planning. The findings highlight the significance of tailored dose planning, organ-specific adverse effects, optimum treatment regimens, the potential for combination therapies, and the advancement of radiopharmaceutical development.